Brokerages Set Aimmune Therapeutics Inc (AIMT) Price Target at $50.56

Share on StockTwits

Aimmune Therapeutics Inc (NASDAQ:AIMT) has been assigned a consensus recommendation of “Buy” from the twelve brokerages that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, four have issued a hold rating and seven have assigned a buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $50.56.

Several equities analysts have recently issued reports on the company. Wedbush restated an “outperform” rating and set a $80.00 target price on shares of Aimmune Therapeutics in a research report on Tuesday, February 5th. BidaskClub upgraded Aimmune Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, February 4th. ValuEngine lowered Aimmune Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, February 4th. Zacks Investment Research upgraded Aimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, February 4th. Finally, Credit Suisse Group reiterated a “buy” rating and set a $40.00 price objective on shares of Aimmune Therapeutics in a report on Tuesday, January 15th.

Shares of Aimmune Therapeutics stock traded up $0.63 during trading on Friday, hitting $24.21. 814,781 shares of the company were exchanged, compared to its average volume of 651,331. The firm has a market capitalization of $1.40 billion, a P/E ratio of -9.28 and a beta of -0.12. Aimmune Therapeutics has a 1-year low of $21.22 and a 1-year high of $42.00.

In other Aimmune Therapeutics news, insider Jayson Donald Alexander Dallas acquired 3,650 shares of the business’s stock in a transaction dated Monday, November 19th. The shares were acquired at an average price of $27.56 per share, for a total transaction of $100,594.00. Following the acquisition, the insider now directly owns 63,600 shares of the company’s stock, valued at approximately $1,752,816. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 14.70% of the company’s stock.

Several large investors have recently added to or reduced their stakes in AIMT. Legal & General Group Plc lifted its stake in Aimmune Therapeutics by 29.1% in the 4th quarter. Legal & General Group Plc now owns 18,273 shares of the biotechnology company’s stock valued at $437,000 after acquiring an additional 4,123 shares in the last quarter. Amundi Pioneer Asset Management Inc. bought a new stake in Aimmune Therapeutics in the 4th quarter valued at approximately $139,000. Opaleye Management Inc. bought a new stake in Aimmune Therapeutics in the 4th quarter valued at approximately $3,588,000. Metropolitan Life Insurance Co. NY lifted its stake in Aimmune Therapeutics by 356.6% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 14,369 shares of the biotechnology company’s stock valued at $344,000 after acquiring an additional 11,222 shares in the last quarter. Finally, Bank of America Corp DE lifted its stake in Aimmune Therapeutics by 2.6% in the 4th quarter. Bank of America Corp DE now owns 531,055 shares of the biotechnology company’s stock valued at $12,702,000 after acquiring an additional 13,679 shares in the last quarter. Institutional investors and hedge funds own 76.17% of the company’s stock.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.

See Also: What is the NASDAQ?

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply